Appili Therapeutics Inc.
APLIF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $1 | $0 | $1 |
| % Growth | -87.9% | 147.6% | -76% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $1 | $0 | $1 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $7 | $6 | $4 | $21 |
| G&A Expenses | $3 | $3 | $4 | $5 |
| SG&A Expenses | $3 | $3 | $4 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$10 | -$6 | -$0 | -$1 |
| Operating Expenses | $0 | $3 | $8 | $25 |
| Operating Income | -$0 | -$2 | -$8 | -$24 |
| % Margin | -190% | -261.4% | -2,326.9% | -1,698.1% |
| Other Income/Exp. Net | -$2 | -$2 | -$1 | -$1 |
| Pre-Tax Income | -$3 | -$4 | -$9 | -$25 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$3 | -$4 | -$9 | -$25 |
| % Margin | -2,613.1% | -457% | -2,765.9% | -1,806.2% |
| EPS | -0.022 | -0.031 | -0.081 | -0.376 |
| % Growth | 30.8% | 61.6% | 78.4% | – |
| EPS Diluted | -0.022 | -0.031 | -0.081 | -0.376 |
| Weighted Avg Shares Out | 121 | 121 | 114 | 67 |
| Weighted Avg Shares Out Dil | 121 | 121 | 114 | 67 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $3 | $2 | $1 | $2 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | -$2 | -$8 | -$24 |
| % Margin | 359% | -249.8% | -2,425.1% | -1,690.7% |